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Abstract
Motivation: Cell lines and patient-derived xenografts (PDXs) have been used extensively to under-
stand the molecular underpinnings of cancer. While core biological processes are typically con-
served, these models also show important differences compared to human tumors, hampering the
translation of findings from pre-clinical models to the human setting. In particular, employing drug
response predictors generated on data derived from pre-clinical models to predict patient response
remains a challenging task. As very large drug response datasets have been collected for pre-
clinical models, and patient drug response data are often lacking, there is an urgent need for meth-
ods that efficiently transfer drug response predictors from pre-clinical models to the human
setting.
Results: We show that cell lines and PDXs share common characteristics and processes with
human tumors. We quantify this similarity and show that a regression model cannot simply be
trained on cell lines or PDXs and then applied on tumors. We developed PRECISE, a novel method-
ology based on domain adaptation that captures the common information shared amongst pre-
clinical models and human tumors in a consensus representation. Employing this representation,
we train predictors of drug response on pre-clinical data and apply these predictors to stratify
human tumors. We show that the resulting domain-invariant predictors show a small reduction in
predictive performance in the pre-clinical domain but, importantly, reliably recover known associa-
tions between independent biomarkers and their companion drugs on human tumors.
Availability and implementation: PRECISE and the scripts for running our experiments are avail-
able on our GitHub page (https://github.com/NKI-CCB/PRECISE).
Contact: l.wessels@nki.nl
Supplementary information: Supplementary data are available at Bioinformatics online.
1 Introduction
Cancer is a heterogeneous disease that arises due to the accumula-
tion of somatic genomic alterations. These alterations show high lev-
els of variability between tumors resulting in heterogeneous
responses to treatments. Precision medicine attempts to improve re-
sponse rates by taking this heterogeneity into account and tailoring
treatment to the specific molecular make-up of a given tumor. This
requires the identification of biomarkers to identify the set of
patients that will benefit from a given treatment while sparing those
that will not benefit the unnecessary side-effects. However, as there
are limited patient response data for a wide range of drugs, pre-
clinical modes, such as cell lines and patient-derived xenografts
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(PDXs) have been employed to generate large-scale datasets that en-
able the development of personalized treatment strategies based on
the data-driven identification of biomarkers of response. More spe-
cifically, hundreds of pre-clinical models have not only been exten-
sively molecularly characterized, but, more importantly, their
response to hundreds of drugs has also been recorded. This has
resulted in large public resources containing data derived from cell
lines (GDSC1000, Iorio et al., 2016) and PDX models (NIBR
PDXE, Gao et al., 2015).
These pre-clinical resources can be employed to build predictors
of drug response which are then transferred to the human setting,
allowing stratification of patients for drugs the patients have not yet
been exposed to. Geeleher et al. applied this approach by simply cor-
recting for a batch effect between the cell line and tumor datasets
and then directly transferring the cell line predictor to the human
setting (Geeleher et al., 2014, 2017). This already yielded some
promising results: it recovered well-established biomarkers such as
the association between Lapatinib sensitivity and ERBB2 amplifica-
tions. However, when directly transferring a predictor from the
source domain (cell lines) to the target domain (human tumors) one
assumes that the source and target data originate from the same dis-
tribution. While the differences between pre-clinical models and
human tumors have been studied extensively (Ben-David et al.,
2017,2018; Gillet et al., 2013), the most obvious differences include
the absence of an immune system in both cell lines and PDXs and
the absence of a tumor micro-environment and vasculature in cell
lines. One can therefore not assume similarity between the source
and target distributions.
Transfer learning aims at addressing this issue (see Pan and
Yang, 2010 for a general review). Transfer learning methods can be
assigned to different categories depending on the availability of
source and target labels and on the specific relation between these
source and target datasets. Since we have a very small number of
labeled tumor samples, but a wealth of labeled pre-clinical models,
our approach falls into the category referred to as transductive
[while this terminology is not widely used in the community, we fol-
low the categorization employed in Pan and Yang (2010)]. Since the
features (i.e. the genes) are the same in the source and target
domains, our problem requires a domain adaptation strategy, some-
times also referred to as homogeneous domain adaptation.
As previously mentioned, the marginal distributions of pre-
clinical models and tumors are expected to be different. However,
we assume that drug response is, for a large part, determined by bio-
logical phenomena that are conserved between pre-clinical models
and human tumors. Therefore there should exist a set of features
(genes) for which the conditional distribution of drug response given
these features is comparable across cell lines, PDXs and human
tumors. Different methodologies have been proposed to find such a
common space and these can be divided in two main categories
(Csurka, 2017). For approaches in the first category, called data-
centric, a common subspace can be found directly from both the
pre-clinical models and the tumors by aligning the marginal distribu-
tions. This can be done by, for instance, using the Maximum Mean
Discrepancy either exactly or employing semi-definite-programming
(Pan et al., 2008; Song et al., 2008), or by using approximations
based on multiple-kernel learning (Duan et al., 2012) or empirical
kernel maps (Pan et al., 2011). Approaches in the second category,
called subspace-centric, perform the domain adaptation correction
by first reducing the dimensionality, and then aligning the low-rank
representations (Fernando et al., 2013; Gong et al., 2012; Gopalan
et al., 2011). In the first category, the marginal distributions are dir-
ectly aligned, suggesting that the empirical distribution would
sufficiently accurately reflect the real behavior of the source and tar-
get samples. If, for instance, the source dataset consists of a propor-
tion of ER positive samples that is very different from the target
dataset, such a direction would be discarded as it is too dissimilar
between the source and target. Clearly, this would be undesirable, as
it represents a very important variable in breast cancer. The second
category does find the directions of important variations, and then
compares these directions between source and target. Hence, these
approaches do not directly compare the distribution and are less
subject to the sample size issue and to sample selection bias. We
chose to employ the latter approach.
We present Patient Response Estimation Corrected by
Interpolation of Subspace Embeddings (PRECISE), a methodology
based on domain adaptation that trains a regression model on proc-
esses that human tumors share with pre-clinical models. Figure 1
shows the general workflow of PRECISE. We first independently ex-
tract factors from the cell lines, PDXs and human tumors by means
of linear dimensionality reduction. We then use a linear transform-
ation that geometrically matches the factors from one of the pre-
clinical models to the human tumor factors (Fernando et al., 2013).
Subsequently we extract the common factors [principal vectors
(PVs)] defined as the directions that are the least influenced by the
linear transformation (Fig. 1A). After selection of the most similar
PVs, we compute new feature spaces (based on this selection) by
interpolating between the source domain (cell line or PDX PVs) and
the target domain (human tumor PVs). The feature spaces resulting
from this interpolation allow a balance to be struck between the
chosen model system and the tumors (Gong et al., 2012; Gopalan
et al., 2011). This approach, although using the notion of canonical
angle differs markedly from Canonical Correlation Analysis. Indeed,
in our case, samples are not paired and no cross-correlation can be
computed. From the set of interpolated spaces, the consensus repre-
sentation is obtained by optimizing the match between the marginal
distributions of the chosen pre-clinical model and the human tumor
data projected on these interpolated features. These consensus fea-
tures are finally used to train a regression model using data from the
pre-clinical model of choice. We use this regression model to predict
tumor drug response (Fig. 1B). As these features are shared between
the pre-clinical models and the human tumors, the regression model
is expected to generalize to human tumors. We finally use known
biomarker-drug associations (from independent data sources, e.g.
mutation status, copy number) as positive controls to validate the
predictions of the model in human tumors (Fig. 1C).
This work contains the following novel contributions. First, we
introduce a scalable and flexible methodology to find the common
factors between pre-clinical models and human tumors. Second, we
use this methodology to quantify the transcriptional commonality in
biological processes between cell lines, PDXs and human tumors,
and we show that these common factors are biologically relevant.
Third, we show how these common factors can be used in regression
pipelines to predict drug response in human tumors and that we re-
cover well-known biomarker–drug associations. Finally, we derive
an equivalent, faster and more interpretable way to compute the
geodesic flow kernel, a widely used domain adaptation method in
computer vision. Our approach builds up on the work of Gopalan
et al. (2011) and Gong et al. (2012) but extend these approaches by
first removing irrelevant non-transferable information automatical-
ly, and second by finding consensus features within the interpolation
scheme to counter the bias towards source features induced by
Ridge regression.
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2 Materials and methods
2.1 Notes on transcriptomics data
We here present the datasets employed in this study. Further notes
on preprocessing can be found in Supplementary Subsection 1.3.
2.1.1 The cell line dataset
We used the GDSC1000 dataset to train predictors on the cell lines.
GDSC1000 contains IC50-values for a wide range of drugs.
Amongst these drugs, we restricted ourselves to drugs that are either
cytotoxic chemotherapies or targeted therapies and have shown an
effect on at least one cancer type. This resulted in a set of 45 drugs
employed in this study (Supplementary Subsection 1.2). The gene
expression profiles of 1031 cell lines are available in total, including
51 breast cancer and 40 skin melanoma lines. Gene expression data
are available in the form of FPKM and read counts.
2.1.2 The PDX dataset
We used the Novartis PDXE dataset which includes the gene expres-
sion profiles of 399 PDXs, including 42 breast cancer PDXs and 32
skin melanoma PDXs. Transcriptomics data are available in the
form of FPKM.
2.1.3 The human tumor dataset
We extracted gene expression profiles for human tumors from The
Cancer Genome Atlas. Specifically, we employed gene expression
profiles for 1222 breast cancers and 472 skin melanoma cancers.
Both FPKM and read counts are available. Mutation and copy num-
ber aberrations have been downloaded from the cBioPortal (Gao
et al., 2013). Translocation data have been downloaded from
TumorFusions (Hu et al., 2018).
2.2 The cosine similarity matrix
Transcriptomics data are high-dimensional with p  19:000 features
(genes) and since these genes are highly correlated, only some com-
binations of genes are informative. A simple—yet robust (Van Der
Maaten et al., 2009)—way to find these combinations is to use a lin-
ear dimensionality reduction method, like Principal Components
Analysis (PCA), that breaks the data matrix down in df factors
Fig. 1. Overview of PRECISE and its validation. (A) Human tumor and pre-clinical data are first processed independently to find the most important domain-specif-
ic factors (using, for instance PCA). These factors are then compared, aligned and ordered by similarity, yielding PVs. The first PVs are pairs of vectors that are
geometrically very similar and capture strong commonality between human tumors and pre-clinical models, the PVs at the bottom represent dissimilarities be-
tween human tumors and pre-clinical models. (B) A cut-off in similarity enables the retention of processes that are common. After interpolation between these
most similar pre-clinical and tumor PVs, a consensus representation is computed by balancing the influence of human tumor and pre-clinical PVs. We performed
a gene set enrichment analysis on these features to assess that they were clinically relevant. A tumor-aware regression model is finally trained by projecting pre-
clinical and human tumor transcriptomics data on this consensus representation. (C) In order to validate our model, we use positive controls from independent
data sources such as copy number or mutation data. These positive controls are established biomarker–drug associations. We compare the predictions of our
model to predictions obtained based on these independent established biomarkers. Red boxes highlight our contributions
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independently for the source (cell lines or PDXs) and target (human
tumors) such that
8i 2 s; tf g; Xi ¼ SiPi with PiPTi ¼ Idf ; (1)
where s and t refer to the source and target, respectively; X repre-
sents the (n x p) transcriptomics dataset where each row represents
a sample and each column a gene; Idf is the identity matrix and P 2
R
dfp contains the factors in the rows (i.e. the principal compo-
nents). Since these factors are computed independently for the
source and the target, we refer to them as domain-specific factors.
Here we only consider PCA since it is widely adopted by the com-
munity, and for its direct link to variance that acts as a first-order
approximation in the comparison of distributions. Our method is,
however, flexible and any linear dimensionality reduction method
can be used.
Once domain-specific factors have been independently com-
puted for both the source and target, a simple way to map the
source factors to the target factors is to use the subspace alignment
approach suggested by Fernando et al. (2013). This approach finds
a linear combination (M) of source factors that reconstructs the
target factors as closely as possible:
M ¼ argmin
M2Rdf df
jjPTs M PTt jjF ¼ PsPTt ; (2)
which is the least squares solution under orthogonality constraints
from Equation (1). This optimal transformation consists of the
inner product between the source and target factors and therefore
quantifies the similarity between the factors. We will therefore refer
to it as the cosine similarity matrix. It is also referred to as Bregman
matrix divergence in the literature.
2.3 Common signal extraction by transformation
analysis
As we will show in Subsection 3.1, matrix M is far from diagonal,
indicating that there is not a one-to-one correspondence between the
source- and target-specific factors. Moreover, using M to map the
source-projected data onto the target domain-specific factors would
only remove source-specific variation, leaving target-specific factors
and the associated variation untouched.
To understand this transformation further, we performed a sin-
gular value decomposition (SVD), i.e. PsP
T
t ¼ UCVT , where U and
V are orthogonal of size df and C is a diagonal matrix. U and V de-
fine orthogonal transformations on the source and target domain-
specific factors, respectively, and create a new basis for the source
and target domain-specific factors:
sk ¼ PTs U
 
:;k
and tk ¼ PTt V
 
:;k
for all k 2 1; ::; df
 
: (3)
These define the principal vectors (PVs) (Golub and Van Loan,
2012) that have the following equivalent definition:
8k 2 1; ::df
 
; sk; tk ¼ argmax
s2span Psð Þ; t2span Ptð Þ
sTt
s:t 8i < k; si?s
ti?t and s
Ts ¼ tTt ¼ 1:
 (4)
s1; ::; sdf define the same span as the source-specific factors—and so
do t1; ::; tdf with the target-specific factors. PVs thus retain the same
information as the original domain-specific factors, but their cosine
similarity matrix (C) is diagonal. The PVs s1; t1ð Þ; ::; sdf ; tdfð Þ
 
are
derived from the source and target domain-specific factors and
the pairs are sorted in decreasing order based on their similarity.
The top PVs are very similar between source and target while the
bottom pairs are very dissimilar. For this reason we restricted the
analysis to the top dpv PVs. In Equation (4), PVs have been defined
as unitary vectors that maximize the inner product. The similarities
therefore range between 0 and 1, and can thus be interpreted as the
cosines of principal angles defined as
8k 2 1; ::df
 
; hk ¼ arccos sTk tk
 
: (5)
We define Qs and Qt as the matrix with the ordered PVs of the
source and the target, respectively, with the factors in the rows.
2.4 Factor-level gene set enrichment analysis
In order to associate the PVs and the consensus representation with
biological processes, we use Gene Set Enrichment Analysis
(Subramanian et al., 2005). For each factor (i.e. a PV or a consensus
factor), we projected the tumor data onto it, yielding one score per
tumor sample. These sample scores where then used in the GSEA
package as continuous phenotypes. We employed sample-level per-
mutation to assess significance based on 1000 permutations. We
used two curated gene sets from the MSigDB package: the canonical
pathways and the chemical and genetic perturbations.
2.5 Building a robust regression model
Given the common factors, we can create a drug response pre-
dictor based on these pairs of PVs. There are different ways to use
these pairs of PVs. We could restrict ourselves to either the source or
target PVs, but it would only support one of the two domains.
Alternatively, we could use both source and target PVs. However,
this would also be sub-optimal for the following reason. Source PVs
are computed using the source data and maximize the explained
variance of the source. Hence the source data projected on the
source PVs is likely to have higher variance than the source data pro-
jected on the target PVs, since target PVs have not been optimized
Algorithm 1 PRECISE
Require: source data Xs, target data Xt, number of domain-
specific factors df, number of PV dpv.
Ps  df source domain-specific factors (e.g. Principal
Components)
Pt  df target domain-specific factors (e.g. Principal
Components)
U;V;C SVD of PsPTt ¼ UCVT
Qs  ðPTs UÞT
Qt  ðPTt VÞT
U ¼ UQs ;Qt as specified in Equation (7)
for i 1 to dpv do
Si  ½Uið0Þ;Uið0:01Þ; ::;Uið1ÞT
X
proj
s;i ¼ XsSi
X
proj
t;i ¼ XtSi
si  time of optimal matching between columns of Xprojs;i
and X
proj
t;i
end for
F ½U1ðs1Þ;U2ðs2Þ; ::;Udpv ðsdpv ÞT
Xprojs  XsF
Xprojt  XtF
Train a regression model on Xprojs
Apply it on the projected target data Xprojt .
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for the source data. If we were to apply penalized regression on the
source data projected on both the source and target PVs, it would
preferably select the source PVs. This would in turn lead to a loss of
generalizability as source-specific information is weighed more
heavily that target-specific information.
One way to circumvent this issue is to construct a new feature
space using ‘intermediate’ features based on interpolation between
the spaces spanned by the source and target PVs. For instance, in the
plane that joins s1 and t1, the rotations from the former to the latter
vector could contain a better representation. The intermediate fea-
tures are expected to be domain invariant as they represent a trade-
off between source and target domains and can thus be used in a
regression model.
There are an infinite number of parameterizations for the inter-
mediate features that join the source to the target PVs. As suggested
in Gopalan et al. (2011) and Gong et al. (2012), we consider the
geodesic flow representing the shortest path on the Grassmannian
manifold. We derive (see Supplementary Subsection 2.2 for the com-
plete proof) a parameterization of the geodesic as a function of the
PVs. Let’s defineP and N as
8s 2 0; 1½ ;
P sð Þ ¼ diag sin 1 sð Þhi
 
sin hið Þ
 !
i
N sð Þ ¼ diag sin shið Þ
sin hið Þ
	 

i
;
8>><
>>:
(6)
where diag ð Þ is the diagonal matrix. The intermediate representa-
tions are then defined by the geodesic path that corresponds to a ro-
tation for each pair of PVs:
U : s 2 0;1½ 7!QTs P sð Þ þQTt N sð Þ : (7)
This geodesic path contains, for each pair of PVs, the features
forming a rotating arc between the source and the target PVs. This
formulation of the geodesic flow has the advantage of being based
on the PVs, and not the domain-specific factors, in contrast to the
formulation used in Gopalan et al. (2011) and Gong et al. (2012).
Non-similar PVs can be removed prior to interpolation.
However, we show in Supplementary Subsections 2.3 and 2.4
that projecting on all these features is equivalent, even in the infinite
case, to projecting onto both the source and the target PVs, with the
undesirable consequences described above. It is therefore preferable
to create, for each pair of PVs, a single interpolated feature that
strikes the right balance between the information contained in the
source and target spaces. Consequently, a regression model trained
on source data projected on the interpolated feature would general-
ize better on the target space. To construct these interpolated, or
consensus features, we use the Kolmogorov–Smirnov (KS) statistic
as a measure of similarity between the source and target data, both
projected on a candidate interpolated feature.
Specifically, by denoting dpv as the number of selected PVs, for
i 2 1; ::; dpv
 
and s 2 0; 1½  the feature at position s between the ith
pair is defined as Ui sð Þ ¼ U sð Þð Þ;i. For each pair of PVs, we then se-
lect the position si that minimizes the KS statistic between the distri-
butions of the source and target data projected on this feature. Let
denote by D the KS statistic between the two projected datasets. We
thus define si as:
si ¼ min
s2 0;1½ 
D XsUi sð Þ;XtUi sð Þð Þ: (8)
This optimization is performed using a uniformly spaced grid
search in interval 0; 1½  with step size 0.01, moving between the
source and the target.
This process is repeated for each of the top dpv PVs, resulting in
an optimal interpolation position for each. These positions are then
plugged back into the geodesic curve to yield the domain-invariant
feature representation F defined as:
F ¼ U1 s1ð Þ;U2 s2ð Þ; :: ;Udpv sdpvð Þ
 T : (9)
The source data can now be projected on these features and the
resulting dataset can be used for training a regression model that can
be more reliably transferred to the target (human tumor) data.
2.6 Notes on implementation
Once the number of principal components and PVs have been set
(see Supplementary Subsection 5 for an example), the only hyper-
parameter that needs to be optimized is the shrinkage coefficient (k)
in the regression model. We employed a nested 10-fold cross-valid-
ation for this purpose. Specifically, for each of the outer cross-valid-
ation folds, we employed an inner 10-fold cross-validation on 90%
of the data (the outer training fold) to estimate the optimal k. To
this end, in each of the 10 inner folds, we estimated the common
subspace, projected the inner training and test fold on the subspace,
trained a predictor on the projected inner training fold and deter-
mined the performance on the projected inner test fold as a function
of k. After completing these steps for all 10 inner folds, we deter-
mined the optimal k across these results. Then we trained a model
with the optimal k on the outer training fold and applied the predict-
or to the remaining 10% of the data (outer test fold). We then
employed the Pearson correlation between the predicted and actual
values on the outer test folds as a metric of predictive performance.
Note that every sample in an outer test folds is never employed to
perform either domain adaptation nor in constructing the response
predictor in that same fold.
The methodology presented in this section is available as a
Python 3.7 package available on our GitHub page. The domain
adaptation step has been fully coded by ourselves and the regression
and cross-validation uses scikit-learn 0.19.2 (Pedregosa et al.,
2011).
3 Results
3.1 Pre-clinical models and human tumors show limited
similarity
The cosine similarity matrix M presented in Subsection 2.2 gives an
indication of the similarity between the source and the target princi-
pal components. A clear correspondence between factors would
yield a diagonal matrix, allowing a single target principal compo-
nent to be assigned to a single source principal component. Using
data presented in Subsection 2.1, Figure 2A and C instead, show
that this is clearly not the case as each source principal component
shows similarity to a number of target principal components.
Roughly speaking, for cell lines (Fig. 2A), the top four source factors
show high similarity with the top ten target factors. The similarity
between PDXs and human tumor principal components is generally
higher and holds for a larger set of factors (Fig. 2C). This is to be
expected since PDXs are believed to show higher resemblance to
human tumors than cell lines.
When tumor data are projected on the cell line principal compo-
nents, the explained variance accounts for around 30% of the vari-
ance explained when mapping the data on the human tumor
principal components (Fig. 2B). For PDXs, on the other hand, this
amounts to 40% (Fig. 2D), again indicating that PDXs resemble
tumors more closely than cell lines. The bootstrap confidence
i514 S.Mourragui et al.
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intervals obtained by bootstrapping the tumor samples show that
the obtained variance proportions differ significantly (Fig. 2B and
D). However, for both model systems, the explained variance is rela-
tively small, indicating that the data for both model systems are not
drawn from the same probability distribution as the human tumors,
underscoring the need for a proper alignment of the datasets prior to
transferring a predictor from the pre-clinical modes to the human
tumors.
In order to show that some gene-level structure is shared between
these systems, we permuted the order of the genes in the source data
only. We then computed the cosine similarities and target explained
variance as before (Supplementary Subsection 3.2). Neither the co-
sine similarity values, nor the variance explained were as high as for
the original unshuffled data, suggesting that model systems and
tumor cells do share some feature-level structure. We also compared
the target data to samples drawn uniformly from a Gaussian with a
random covariance matrix in order to study whether the similarity
between source and target data is significant. As shown in
(Supplementary Subsection 3.3), this also yields values three to four
orders of magnitude lower than observed. This all shows the exist-
ence of a shared signal between source and target.
3.2 PVs capture common biological processes
The source and target principal components are employed to com-
pute the ‘common factors’ or PVs for both the source and target
(see Subsection 2.3). Figure 3A shows that the source and target
PVs exhibit a perfect one-to-one correspondence. This is not unex-
pected since, by construction, this cosine similarity matrix is the
central diagonal matrix (C) in the SVD of the optimal transform-
ation between source and target [Equation (2)]. The source and
target PVs are directions that respectively support the source and
the target variance and are ranked by their pairwise similarity.
When 20 principal components are computed between breast cell
lines and breast tumors, the similarity between the PVs ranges
from 0.78 to 0.02, indicating that the low ranking pairs are almost
orthogonal. Although 0.78 could seem like a low value for the top
similarity, such a value remains significantly large for a 19 000-di-
mensional space. Supplementary Figure S5A depicts the top 20
PVs obtained for breast PDXs and breast tumors and shows that
the top similarity coefficients are higher than for cell lines, as
expected.
To determine how PVs are related to genes, we calculated the
contribution of each gene to the PVs. We subsequently employed
these contributions in a gene set enrichment analysis (see Subsection
2.4) to compute the association between the pathways in a given
data base and the PVs. This resulted in a vector of pathway scores
for every PV. We then computed the pathway similarity between a
pair of PVs as the correlation of the pathway scores. Figure 3B
shows these correlations for the top 20 pairs of cell line and human
tumor PVs for six different pathway databases. Correlations are
Fig. 2. Comparison of domain-specific factors between source and target with the source being cell lines (A, B) or PDXs (C, D). (A, C) The absolute cosines similar-
ity, i.e. the absolute values of the scalar products between source and target domain specific factors. High similarities are found between some factors but no
clear 1–1 correspondence is visible (absence of high values on the diagonal). (B, D) The ratio of tumor variance explained. Human tumor data were projected on
the source and target PVs, the variance of the projected data on each direction was computed and divided by the total human tumor variance. The shaded regions
represent the 98% confidence intervals obtained by bootstrapping the human tumor samples. Overall, the first five cell line factors each explain more than 1% of
the human tumor variance each, while for PDXs this is achieved for the first seven factors. The non-monotonic behavior of the PDX and cell line principal compo-
nent curves shows that the human tumor variance is not supported by the same directions than the pre-clinical models, which necessitates domain adaptation.
PDXs show slightly higher similarity to human tumors than cell lines
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close to one for the first PVs, indicating high pathway similarities,
whereas the pathway similarity decreases (even becoming negative)
for the lower ranked PVs. Taken together this shows that the PVs
capture shared pathway information between the model systems
and the human tumors.
When zooming in on the individual pathway similarities, we ob-
serve roughly two types of behaviors (Fig. 3C and D). First, some
gene sets show significant enrichment for the top PVs as well as
lower ranked PVs. These gene sets are related to breast cancer sub-
types, cell cycle and DNA replication, i.e. gene sets one would ex-
pect to be enriched in both cell lines and human tumors. Second,
some gene sets show enrichment for the more dissimilar PVs. Most
of these gene sets are related to the response of the immune system
and the extra-cellular matrix, entities which are not fully present in
the cell lines. Supplementary Figure S5C shows the results of the
gene set enrichment analysis for breast PDXs and human tumors.
We observe roughly the same behavior as for the cell lines and
human tumors, especially regarding the gene sets enriched in the top
PVs and the enrichment of immune related sets. However, we do ob-
serve that the extra-cellular matrix shows enrichment in higher
ranked PVs (PV 5 and 7) which is in line with what one would ex-
pect in a PDX model. Taken together, this indicates that the PVs
that are most similar between pre-clinical models and human tumors
provide a mechanism to capture the information shared between
Fig. 3. PVs computed from breast cell lines and breast tumors from 20 principal components. (A) The Cosine Similarity matrix for cell line and tumor PVs. The val-
ues on the diagonal show the similarities within the corresponding pairs of PVs. Similarity starts at 78% and goes down to 2% for the last pair (not shown). The
off-diagonal values are almost zero, showing that pairs of PVs of unequal rank are orthogonal to one another. (B) The Spearman correlations between the
Normalized Enrichment Scores (NES) of source and target PVs for the different gene sets employed. The top PVs show similar enrichments while the bottom
ones show little similarity, even negative correlation. This shows that top PVs represent the same biological phenomena. (C) The NES based on the canonical
pathways for each PV pair with the NES for the source PV on the left and the NES for the target PV on the right (separated by a dashed line). Non-significant gene
sets are represented as white cells. For this figure panel, we selected the 10 gene sets that were most highly enriched in the first five PVs, the 10 gene sets that
showed the highest enrichment in the bottom PVs as well as all the gene sets related to extra-cellular matrix. The top PVs are exclusively enriched in pathways
related to cell cycle. Immune system-related pathways are enriched in the middle and bottom PVs and PVs at the bottom tend to show enrichment for the target
PVs only. (D) The NES for each PV as displayed in (C), for the CHARAFE and VANTVEER gene sets. The top PVs are significantly enriched in sets associated with
breast cancer subtypes
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model systems are tumors, while discarding processes that behave
differently.
3.3 The consensus representation yields reduced but
competitive performance
Using PRECISE, we have derived a consensus feature representation
which is both biologically informative and shared between the
source and target. This representation can be used in a regression
model trained on the source drug response data. Since Jang et al.
(2014) demonstrated that regularized linear models such as Ridge
regression or ElasticNet (Zou and Hastie, 2005) yield state-of-the-
art performance for drug response prediction and since it is widely
used, we will be employing Ridge regression.
We computed the predictive performance of PRECISE for 84
drug and tumor type combinations (Supplementary Subsection 1.2).
For a given drug and tumor type combination, we used PRECISE
with all cell lines—i.e. the 1.001 cell lines across the 31 tissue
types—as source and the corresponding tumor type as target. For
example, to predict response to Vemurafenib in melanoma, we used
all the cell lines from the GDSC panel, regardless of tumor type, as
source, and melanoma tumors from The Cancer Genome Atlas as
target. We used 70 principal components since the variance
explained shows a plateau after 70 principal components
(Supplementary Subsection 5.1). For the selection of the top PVs, we
compared the obtained similarity values of the source and target
PVs to the similarities obtained with random data and put the cut-
off at the top 40 PVs (Supplementary Subsection 5.2). We then com-
puted the interpolated feature space employing the KS statistic and
employed this feature space in the subsequent Ridge regression
models.
As shown in Figure 4A, PRECISE achieves predictive performan-
ces that are reduced but comparable with a Ridge regression model
trained on the raw cell line gene expression data. The Pearson cor-
relation between Ridge regression and PRECISE performance is
r ¼ 0.97 with a median relative reduction in Pearson correlation of
0.039. As it is the aim of the consensus representation to focus on
the commonalities between the cell lines and the human tumors, it is
to be expected that such a representation will not fully capture the
variation in the cell lines as it is also adapted to the variation in the
human tumors. Hence, a small drop in performance is not unexpect-
ed, as long as it results in improved predictions on the human tumor
data, which we will demonstrate in the next section.
3.4 Domain-invariant regression models recover bio-
marker–drug associations
To validate our predictor on human tumor data, we follow Geeleher
et al. (2017) by comparing the prediction in human tumors with the
performance of independent, known biomarkers. Since we exclu-
sively use gene expression to stratify patients in terms of their re-
sponse to a certain therapy, we can use known biomarkers derived
from other data sources—e.g. mutations or copy number changes—
to create an independent response stratification of the human
tumors against which we can compare our approach. In order to
predict the IC50 in human tumor, we trained PRECISE using all the
cell lines, irrespective of their tissue of origin, and the corresponding
tumor type.
The first known and clinically employed association between a
biomarker and response to a drug that we tested is the association
between the presence of an ERBB2 amplification and response to
Lapatinib in breast cancer. Since Lapatinib specifically targets the
ERBB2 growth factor, breast tumors that overexpress this growth
factor, and are therefore addicted to this signal, respond well to this
therapy. An accurate stratification of the breast tumors by PRECISE
would therefore show a negative association with the level of
ERBB2 amplification in the tumors, as the tumors predicted to be
most sensitive (lowest IC50) would show the highest level of ERBB2
copy number amplification. This is exactly what we observe in
Figure 4B, where the predicted IC50 and the observed ERBB2 copy
number amplification level show a Spearman correlation of
q ¼ 0:32. In addition, the copy number loss and copy number neu-
tral categories show statistically significant differences in predicted
IC50 compared to the samples harboring a copy number gain.
The second known association that we investigated is the associ-
ation between the presence of a BRAFV600E mutation and response
Fig. 4. Predictive performance assessment. (A) Scatterplot of the performance of PRECISE and Ridge regression. Predictive performance for each approach was
computed as the Pearson correlation between the measured and the 10-fold cross-validated predicted IC50s. PRECISE and Ridge regression performance is
strongly correlated, with PRECISE showing a slight drop in performance. (B) Predicted drug response (predicted IC50) for breast tumors based on a predictor of
Lapatinib response trained on all the cell lines—i.e. across all tissue types—employing gene expression data only. ERBB2 copy number status in tumors corre-
lates significantly with predicted IC50 values, validating the predictions, as tumors with ERBB2 amplifications are known to be more sensitive to Lapatinib. (C)
Predicted drug response (predicted IC50) for skin melanoma tumors based on a predictor of Tramatinib response trained on all the cell lines—i.e. across all tissue
types—employing gene expression data only. The PRECISE predictions are validated by the established fact that BRAFV600E-mutated tumors show a significantly
higher sensitivity while the tumors bearing other mutations in BRAF do not show responses that differ from wild-type tumors
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to MEK inhibitors in skin melanomas, while other BRAF mutations
have not exhibited this association. As shown in Figure 4C, the
IC50s predicted for Trametinib by PRECISE show a significant dif-
ference between tumors bearing a BRAFV600E mutation and tumors
that are wild-type for this gene. In addition, the PRECISE predic-
tions also show a significant difference in predicted Trametinib re-
sponse between tumors bearing a BRAFV600E mutation and tumors
bearing other mutations in this gene.
Other known associations we tested against are shown in
Supplementary Figure S9: Dabrafenib sensitivity predicted by
BRAFV600E mutations (Supplementary Fig. S9A), Vemurafenib sensi-
tivity predicted by BRAFV600E (Supplementary Fig. S9B) mutations,
Imatinib sensitivity predicted by BCR/ABL translocations in Acute
Myeloid Leukemia (Supplementary Fig. S9C), Olaparib sensitivity
predicted by BRCA1 deletion in breast cancer (Supplementary Fig.
S9D) and Talazoparib sensitivity predicted by BRCA1 deletion in
breast cancer (Supplementary Fig. S9E). These results have been
computed using all the cell lines as source. When using solely cell
lines from the tissue under consideration, the same results are
observed, with a larger difference in predicted sensitivity for
BRAFV600E mutated tumors for Trametinib (Supplementary Fig.
S9G), Dabrafenib (Supplementary Fig. S9H) and Vemurafenib
(Supplementary Fig. S9I), and a very clear separation of BCR/ABL
translocated tumors from the rest under Imatinib treatment
(Supplementary Fig. S9J).
Finally, we compared results from PRECISE with two baseline
approaches. We replicated results from Geeleher et al. (2017) by
employing Ridge regression on either the raw or ComBat corrected
gene expression data. Correcting for batch effect with ComBat pro-
vides a baseline comparison for our methodology. Lapatinib sensi-
tivity is predicted as well as by PRECISE (Supplementary Fig. S10A)
with or without the ComBat preprocessing step. For Dabrafenib, the
association with BRAFV600E is recovered, with and without
ComBat. However, while the strength of the association obtained
with ComBat is comparable to the association recovered with
PRECISE, the strength diminishes without ComBat preprocessing
(Supplementary Fig. S10C). In contrast to PRECISE, neither Ridge
regression nor Ridge regression in combination with ComBat were
able to recover the association between the BRAFV600E mutation
and Trametinib.
In summary, PRECISE is capable of retrieving all tested associa-
tions between known biomarkers and drug response, while current
state-of-the-art approaches fail to recover all these associations.
4 Discussion
Using high throughput sequencing and screening technologies, scien-
tists have leveraged the versatility of pre-clinical models over the
past decade to create powerful predictors of drug response.
However, due to the intrinsic differences between cell lines, PDXs
and real human tumors, these predictors cannot be expected to dir-
ectly translate to the human setting. We have quantified the overlap
in terms of the transcriptomics signal between these pre-clinical
models and human tumors. We then introduced PRECISE, a domain
adaptation framework that finds shared mechanisms between pre-
clinical models and human tumors that display the same behavior
across these systems.
PRECISE generates PVs, pairs of factors that capture the com-
mon variance between pre-clinical models and human tumors. The
top pairs of PVs are most similar, and thus recapitulate molecular
behavior shared between the systems. The least similar PVs, can be
discarded since they correspond to mechanisms not shared across
systems.
These vectors depend on the choice of linear dimensionality re-
duction methods employed. We employed PCA, but other methods
have been proposed in the literature (e.g. Argelaguet et al., 2018;
Bismeijer et al., 2018), all having different qualities (e.g. being bio-
logically meaningful, filtering out noise, etc.). The versatility of our
method enables the use of any dimensionality reduction scheme, as
long it finds an informative linear subspace.
Interpolation between the source and target PVs gives rise to fea-
tures that balance the contribution of pre-clinical models and
tumors. We showed (Supplementary Section 2) that interpolating
between the PVs is equivalent to employing the Geodesic Flow
Kernel approach that relies on the geodesics on the Grassmannian
manifold (Gong et al., 2012) and has already yielded state-of-the-art
performance in Computer Vision.
Recently, other ways to interpolate between the source and the
target domains have been proposed, such as Caseiro et al. (2015)
that use a spline instead of the geodesic. We devised a simple, yet ef-
fective interpolation scheme between the source and target PVs
where we employed the similarity based on the KS statistic between
the source and target data projected on the interpolated space to ar-
rive at a consensus representation. This representation strikes the
right balance between the pre-clinical models and the human
tumors.
We subsequently projected the data on this consensus representa-
tion and trained a regression model which takes the distribution of
the tumor gene expression data into account. This work considered
Ridge and ElasticNet, but our approach is versatile and can be
employed in combination with any classification or regression
approach.
We showed that a Ridge regression model based on the consen-
sus representation achieves slightly reduced performance compared
to state-of-the-art approaches applied directly to the raw cell line
gene expression data. This is to be expected, as the consensus repre-
sentation filters out cell line specific information while capturing
more relevant tumor variation, hence enabling efficient transfer to
the tumor samples.
We finally compared our predictions to the performance of
known biomarkers such as BRAFV600E in skin cancer or ERBB2
amplification in breast cancer and show that our method can reli-
ably recover the associations between these biomarkers and their
companion drugs. We show that response to Lapatinib can be pre-
dicted better when all cell lines are used for domain adaptation. On
the other hand, using all cell lines reduced the power to predict re-
sponse to Vemurafenib, although the resulting association with
BRAFV600E mutation status remained significant. This might be due
to the ubiquity of the ERBB2 amplification in several tumor types,
in contrast to the BRAFV600E mutation that is specific to particular
tumor types.
We restricted our study to domain adaptation based on tran-
scriptomics data only, as it has been shown to be the most predictive
data type (Jang et al., 2014). However, dissimilar behavior between
pre-clinical models and human tumors might also be present in other
molecular data types. A multi-omic drug response predictor should
also correct for these differences, which will require a multi-omic
domain adaptation approach which accommodates the unique data
characteristics of each molecular data type.
Other methods have recently been proposed to tackle the prob-
lem of transferring pre-clinical predictors to human tumors. In
Webber et al. (2018), the authors create a correlation network for
each omics data type and jointly map these networks onto a
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protein–protein interaction network. They then select the cliques
that are conserved across omics-layers. In Normand et al. (2018),
the authors present an elegant framework for fold-change prediction
in humans based on data from mouse models. Using fold-change
data from both humans and mouse, a linear model is fitted at the
gene-level. This linear model is then used to predict fold changes in
human tumors for novel conditions. The problem of translating
from model systems to human has broad applications and we envi-
sion that it will be a very active area of future research.
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